# How to read peptide research: a practical checklist

> Cells, rats or people? Controls, sample size, lab markers, spin, sponsors, retractions and unposted trials, with real peptide examples.

Source page: https://peptioresearch.com/articles/how-to-read-peptide-research/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-13
Type: Methodology

A sentence like "studies show BPC-157 heals tendons" can be true and still say almost nothing about people. The tendon, ligament and muscle healing studies behind that claim were done in rats [1] [2] [3]. The questions below are the ones this site asks of every study before describing it. Each comes with a real example from a peptide already covered here.

## 1. Was it cells, animals or people?

This is the first question because it limits everything after it. A result in cells grown in a dish (in vitro) shows that something can happen in that setting. A result in animals shows it happened in that species, under those conditions. Neither shows it happens in a person. The site's [evidence labels](/methodology/#labels) sort claims by exactly this.

For BPC-157, the fibroblast and blood vessel growth findings are in vitro [4] [5] [6], and the healing findings are in rats [1] [2] [3]. The human record is small and uncontrolled: a chart review [7] [8], a single-arm pilot in 12 women [9], and a report of two adults given infusions [10]. Even between animal species the picture shifts. Bioavailability, the share of a dose that reaches the blood, differed between rats and beagle dogs in a BPC-157 study [11].

### How often do animal results carry over?

The best figure found for this page comes from an umbrella review (a review of reviews) by Ineichen and colleagues in 2024, covering 122 articles, 54 human diseases and 367 therapies [12]. Two of its findings pull in different directions, and both matter. Of therapies studied in animals, 50% progressed to human studies, 40% to randomised trials, and 5% to regulatory approval [12]. Yet where both animal and clinical results existed, the authors found "an 86% concordance between positive results in animal and clinical studies" [12].

So "only 5% of animal findings translate" is half the picture. Most therapies never get a human test that could confirm or refute the animal result. When they do, positive results often agree. Neither number tells you whether a given rat study will hold up in people.

> **Limitation.**
> The Ineichen figures were read from the abstract only, and they describe therapies in general, not peptides.

## 2. Was there a control group, randomisation and blinding?

A control group is a comparable set of subjects who did not get the treatment. Without one, improvement cannot be separated from natural recovery or expectation. Randomisation means chance, not the investigator, decides who gets what. Blinding means participants, and ideally assessors, do not know who got what.

The CONSORT statement, the standard guideline for reporting trials, calls randomised controlled trials "the gold standard" when "appropriately designed, conducted, and reported", and notes that "some poorly conducted or poorly reported aspects of trials were associated with bias" [13]. The Cochrane Handbook's risk-of-bias tool checks five areas: "Bias arising from the randomization process", "Bias due to deviations from intended interventions", "Bias due to missing outcome data", "Bias in measurement of the outcome" and "Bias in selection of the reported result" [14]. On blinding, it says that "if successful", it "should prevent knowledge of the intervention assignment from influencing contamination" [14].

Do not trust a database label for any of this. PubMed indexes a 2002 epitalon report on retinitis pigmentosa, an inherited eye disease, as a controlled clinical trial, but its abstract describes no control group, gives no number of patients and does not define its endpoint [15]. Read what the paper says it did.

## 3. How many subjects?

Small studies are not just less certain. They are biased in a particular direction. Button and colleagues, writing about neuroscience in 2013, found that "the average statistical power of studies in the neurosciences is very low", and that "the consequences of this include overestimates of effect size and low reproducibility of results" [16]. Statistical power is a study's chance of detecting an effect that really exists.

That paper is about neuroscience, not peptides, and its argument carries over only by analogy. The analogy is fair, though: much of the peptide literature rests on a few animals per group or a handful of patients. In female mice given epitalon, at 54 per group, mean lifespan did not change; the reported gains were in maximum lifespan and the last 10% of survivors, which rest on a handful of animals [17].

An absence of reported harm in a tiny uncontrolled study, such as the two BPC-157 infusion cases [10], is not evidence of safety. That is this site's reasoning, not a sourced figure.

## 4. Did it measure something a person feels, or a lab marker?

A surrogate endpoint is a lab value or measurement that stands in for an outcome that matters. FDA defines it as "a clinical trial endpoint used as a substitute for a direct measure of how a patient feels" and adds that it "does not measure the clinical benefit of primary interest in and of itself" [18].

Epitalon offers two examples. A report on middle-aged people found 1.7 times higher urinary excretion of a melatonin breakdown product [19]. That is a surrogate, and the abstract gives no sample size. FDA's 2026 briefing describes the English version of the study as randomised and placebo-controlled, with blinding not specified [20]. In the mouse study above, epitalon "did not influence food consumption, body weight or mean life span"; the gains were in maximum lifespan [17]. Which endpoint ends up in the headline is a choice someone made.

Also check that the substance is the one named. The mortality reductions often attributed to epitalon come from studies of epithalamin, a pineal gland extract, which is a different substance [21] [22] [23].

## 5. Does the abstract match the results?

Most claims online trace back to an abstract, and abstracts can be more favourable than the data. Boutron and colleagues examined 72 reports of randomised trials whose primary outcome was not statistically significant. The title alone carried spin, meaning reporting that makes results look better than they were, in 13 of them (18.0%) [24]. They concluded that "the reporting and interpretation of findings was frequently inconsistent with the results" [24]. Read the results section, and find the primary outcome the study set out to measure.

## 6. Who paid for it, and who ran it?

A 2017 Cochrane methodology review by Lundh and colleagues found that studies sponsored by drug and device makers more often reached favourable conclusions (risk ratio 1.34, 95% confidence interval 1.19 to 1.51, from 29 papers), and that in industry-sponsored studies "there was less agreement between the results and the conclusions" [25]. Its conclusion: "Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results" [25].

That review is about commercial drug and device sponsors. Applying it to peptide research is this site's reasoning, by analogy. Many of the epitalon reports this site cites, including the retinitis pigmentosa report, come from the group that developed it [15]. That does not make the findings wrong. It does mean independent replication is the thing to look for.

## 7. Has the paper been retracted or flagged?

Retraction means the journal has withdrawn the paper. Fang, Steen and Casadevall reviewed 2,047 biomedical and life-science articles that PubMed indexed as retracted, and found "67.4% of retractions were attributable to misconduct" and "only 21.3% of retractions were attributable to error" [26]. Those data run to 2012, so the proportions may have changed since.

For dihexa, the 2014 paper proposing its mechanism, through hepatocyte growth factor and its receptor MET, was retracted in 2025 [27] [28]. A separate 2013 dihexa paper carries a 2021 notice of concern [29]. A mechanism described as "established" may rest on a withdrawn paper.

To check, look at the paper's PubMed record, which shows retraction notices, or the Retraction Watch database, which Crossref acquired in September 2023 and has made publicly available, and which "is updated every working day by Retraction Watch" [30].

## 8. Was the trial registered, and did it post results?

CONSORT asks trial reports to give the "registration number and name of trial registry" [13]. A registration shows that a trial was planned. It does not show that it ran or what it found.

A phase 1 study of BPC-157 was registered in 2015 with an estimated 42 healthy volunteers. Its status is recorded as unknown, no results are posted, and FDA could not find an associated publication [31] [32]. Of three newer registrations, one has completed without posting results [33]; the other two have not yet finished [34] [35]. "Clinically tested" is not a fair description of any of them. The [BPC-157 human evidence](/articles/bpc-157-human-evidence/) article covers what is actually known.

> **Key point.**
> Before believing "studies show", ask four things: was it in people, was there a control group, was the outcome something a person would notice, and is the paper still standing.

Related reading: [Is the FDA banning peptides?](/articles/is-the-fda-banning-peptides/) and the site's [methodology](/methodology/).

## Sources

1. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003. https://doi.org/10.1016/S0736-0266(03)00110-4
2. Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. https://doi.org/10.1002/jor.21107
3. Novinscak T et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today. 2008. https://doi.org/10.1007/s00595-007-3706-2
4. Chang CH et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. https://doi.org/10.3390/molecules191119066
5. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011. https://doi.org/10.1152/japplphysiol.00945.2010
6. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017. https://doi.org/10.1007/s00109-016-1488-y
7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
8. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://doi.org/10.1177/15563316251355551
9. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/39325560/
10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
11. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022. https://doi.org/10.3389/fphar.2022.1026182
12. Ineichen BV et al. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biology. 2024. https://doi.org/10.1371/journal.pbio.3002667
13. Schulz KF et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010. https://doi.org/10.1136/bmj.c332
14. Higgins JPT et al. Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions, version 6.5. Cochrane. 2024. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08
15. Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002. https://pubmed.ncbi.nlm.nih.gov/12195242/
16. Button KS et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience. 2013. https://doi.org/10.1038/nrn3475
17. Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. https://doi.org/10.1023/a:1025114230714
18. Surrogate Endpoint Resources for Drug and Biologic Development. U.S. Food and Drug Administration. 2018. https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
19. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020. https://pubmed.ncbi.nlm.nih.gov/33280326/
20. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193345/download
21. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003. https://pubmed.ncbi.nlm.nih.gov/14523363/
22. Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006. https://doi.org/10.1007/s10517-006-0365-z
23. Korkushko OV et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. 2011. https://doi.org/10.1007/s10517-011-1332-x
24. Boutron I et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010. https://doi.org/10.1001/jama.2010.651
25. Lundh A et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017. https://doi.org/10.1002/14651858.MR000033.pub3
26. Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the United States of America. 2012. https://doi.org/10.1073/pnas.1212247109
27. Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system (RETRACTED). The Journal of Pharmacology and Experimental Therapeutics. 2014. https://doi.org/10.1124/jpet.114.218735
28. Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. The Journal of Pharmacology and Experimental Therapeutics. 2025. https://doi.org/10.1016/j.jpet.2025.103567
29. McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. The Journal of Pharmacology and Experimental Therapeutics. 2013. https://doi.org/10.1124/jpet.112.199497
30. Retraction Watch (Crossref documentation). Crossref. 2023. https://www.crossref.org/documentation/retrieve-metadata/retraction-watch/
31. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. ClinicalTrials.gov. 2015. https://clinicaltrials.gov/study/NCT02637284
32. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193343/download
33. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07752381
34. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07437547
35. Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07803250
